What is the recommended treatment algorithm for psoriasis?

Treatment Algorithm for Psoriasis

For moderate-to-severe plaque psoriasis in adults, methotrexate is recommended as first-line systemic therapy (7.5-25 mg weekly), with biologics—particularly IL-17 inhibitors (ixekizumab, secukinumab) or IL-23 inhibitors (guselkumab, risankizumab)—reserved for second-line treatment after methotrexate failure or as first-line when methotrexate is contraindicated or in patients with concurrent psoriatic arthritis. 1

Disease Severity Classification

• Mild psoriasis: <3% body surface area (BSA) involved 1
• Moderate psoriasis: 3-10% BSA involved 1
• Severe psoriasis: >10% BSA involved, OR any BSA with high-impact locations (face, genitals, palms/soles, nails) causing significant functional or emotional impairment 1

First-Line Systemic Treatment

Methotrexate (Preferred Initial Systemic Agent)

Methotrexate 7.5-25 mg weekly (oral or subcutaneous) is the recommended first-line systemic treatment for moderate-to-severe psoriasis in adults. 1

• Dosing: Start at 7.5-15 mg weekly, can be given as single dose or divided over 24 hours 1
• Route: Subcutaneous administration may improve bioavailability if oral response is inadequate 1
• Test dose: Consider 2.5-5 mg test dose, especially with impaired kidney function 1
• Folic acid supplementation: 1-5 mg daily (except methotrexate day) to reduce GI and hepatic adverse effects; avoid excessive doses (>5 mg) that may reduce efficacy 1

Monitoring Requirements for Methotrexate

Baseline assessment 1:

• Complete blood count (CBC), comprehensive metabolic panel, hepatitis B/C serology, HIV (if risk factors)
• Pregnancy test for women of childbearing potential
• Noninvasive hepatic fibrosis markers (FIB-4, APRI, or ELF) if hepatotoxicity risk factors present

Ongoing monitoring 1:

• Liver function tests and CBC every 3-6 months if stable
• Annual hepatic fibrosis assessment if baseline risk factors present
• Repeat labs in 2-4 weeks if abnormal elevations occur

Contraindications to Methotrexate

Absolute contraindications 1:

• Pregnancy and breastfeeding (teratogenic; wait 3 months after discontinuation before conception)
• Cirrhosis
• Significant thrombocytopenia, leukopenia, or anemia
• Concurrent sulfa drugs (relative; use with caution if necessary)

Second-Line Treatment: Biologics

When methotrexate fails, is contraindicated, or causes intolerable side effects, biologics are recommended, with IL-17 and IL-23 inhibitors preferred over TNF inhibitors for superior efficacy. 1, 2

IL-23 Inhibitors (Highest Efficacy)

Guselkumab or risankizumab are recommended as preferred second-line biologics 2:

• Superior long-term efficacy compared to TNF inhibitors
• Favorable safety profile with lower infection risk than TNF inhibitors
• Dosing: Every 8-12 weeks after loading doses

IL-17 Inhibitors (High Efficacy)

Ixekizumab or secukinumab are recommended alternatives 2:

• Rapid onset of action
• High PASI 90 response rates
• Caution: May trigger or worsen inflammatory bowel disease 3
• Caution: Increased risk of candidal infections 3

TNF Inhibitors (Established Efficacy)

Adalimumab, etanercept, or infliximab remain useful options 1:

• Adalimumab: 80 mg initial dose, then 40 mg week 1, then 40 mg every 2 weeks; some patients require weekly dosing 1
• Etanercept: 50 mg twice weekly for 12 weeks, then 50 mg weekly maintenance 1
• Infliximab: 5 mg/kg IV at weeks 0,2,6, then every 8 weeks; strongly consider adding methotrexate to reduce immunogenicity and antibody formation 1

TNF inhibitors are particularly useful for 3:

• Patients with cardiovascular comorbidities
• Concurrent psoriatic arthritis (all TNF inhibitors effective)

Ustekinumab (IL-12/23 Inhibitor)

• Alternative option with good safety profile 3
• Less efficacious than newer IL-23 selective inhibitors 2

Treatment Goals

Minimum therapeutic target: PASI 75 (75% improvement from baseline) 4

Optimal therapeutic target: PASI 90 or absolute PASI <2 4

• Assess response at 12-16 weeks for most biologics 1
• Switch therapy if minimum target not achieved

Special Considerations

Psoriatic Arthritis

For psoriasis with psoriatic arthritis, biologics are preferred over methotrexate 1:

• Methotrexate has lower efficacy than TNF inhibitors for peripheral arthritis 1
• Methotrexate ineffective for axial involvement 1
• TNF inhibitors, IL-17 inhibitors, or IL-23 inhibitors all effective 1, 3

Specific Psoriasis Subtypes

Palmoplantar psoriasis 1:

• Adalimumab recommended (Strength A)
• Consider cyclosporin as alternative 2

Nail psoriasis 1:

• Adalimumab or etanercept recommended (Strength A)

Pustular or erythrodermic psoriasis 2:

• Cyclosporin for acute flares
• Acitretin for pustular variants
• Biologics for maintenance

Scalp psoriasis 1:

• Adalimumab or etanercept recommended

Combination Therapy

Topical corticosteroids ± vitamin D analogues can be combined with any systemic therapy to augment efficacy 1:

• Strength A recommendation for etanercept + topicals 1
• Strength B recommendation for adalimumab + topicals 1

Methotrexate can be combined with 1:

• Narrowband UVB phototherapy (Strength B) 1
• Biologics (particularly infliximab to reduce immunogenicity) 1

Algorithm for Severe Psoriasis (PASI >12-14)

For patients with baseline PASI >14, methotrexate or cyclosporin are more effective than acitretin 5:

• Consider methotrexate or cyclosporin as first-line
• Acitretin reserved for PASI <14 or hyperkeratotic variants 5

Common Pitfalls

• Inadequate methotrexate trial: Ensure adequate dose (up to 25 mg weekly) and duration (12-16 weeks) before declaring failure 1
• Infliximab without methotrexate: Risk of antibody formation and loss of response; strongly consider concurrent methotrexate 1
• Ignoring comorbidities: Screen for latent tuberculosis before TNF inhibitors, assess IBD history before IL-17 inhibitors 3
• Pregnancy planning: Methotrexate requires 3-month washout before conception 1
• Monitoring gaps: Hepatotoxicity from methotrexate develops over years; maintain regular monitoring even if stable 1